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SUMMARY 
Inhibition of the Wnt signaling pathway is an appealing anti-cancer strategy but most attractive targets are 
involved in proteiŶ‒proteiŶ iŶteraĐtioŶs ;PPIs). Inhibition of such intracellular PPIs is extremely challenging 
since involved proteins are not accessible for biologics and often lack defined binding pockets complicating 
the use of small molecules. In principle, peptide-derived modalities hold the potential to bind flat protein 
surfaces as they are found in PPIs. However, the implementation of robust cellular uptake is complicated 
which hampers their usefulness. Herein, we investigate the cell penetration properties of a stapled peptide 
targetiŶg the iŶteraĐtioŶ ďetǁeeŶ β-catenin and TCF/LEF transcription factors which are crucially involved in 
Wnt signaling. Based on lessons learned from cell-penetrating peptides (CPPs), we design a peptidomimetic 
with excellent cellular uptake ǁhile preserǀiŶg its affiŶitǇ for β-catenin. In cell-based assays, this inhibitor 
shows activity in the low micromolar range exceeding the potency of currently available β-catenin targeting 
agents.  
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INTRODUCTION 
Modified peptides and peptidomimetics represent promising scaffolds for the design of inhibitors of very 
challenging biological targets. In particular, this involves the inhibition of protein–protein interactions (PPIs) 
which, due to the absence of addressable pockets, often prove to be reluctant to a targeting by small 
molecules. Peptides show a propensity to bind flat protein surfaces which are often found in PPI 
interfaces (Pelay-Gimeno et al. 2015; Qvit et al. 2016). However, most peptides are incapable of passing the 
cell membrane which limits their usefulness for the inhibition of intracellular targets. Notably, there are 
exceptions such as cell-penetrating peptides (CPP) which either contain mainly positively charged amino 
acids (polycationic CPPs, e.g. R8 and Tat) or an alternating pattern of charged and hydrophobic side chains 
(amphipathic CPPs) (Ziegler 2008). Primary amphipathic peptides are composed of an isolated hydrophobic 
as well as hydrophilic stretch (e.g. Pep-1). Pep-1 for example consists of a nuclear localization sequence (NLS) 
contributing positive charges and a hydrophobic tryptophan-rich motif (Morris et al. 2007). Secondary 
amphipathic peptides on the other hand (e.g. Penetratin) show their amphipathic character only upon 
adaptioŶ of a defiŶed seĐoŶdarǇ struĐture ;e.g. α-helix) which places hydrophobic and polar residues on 
opposite sides of the molecule (Deshayes et al. 2011; Eiriksdottir et al. 2010).  
Various factors are postulated to support cell surface engagement and penetration of peptides. In 
general, interactions between positively charged amino acids in CPPs and negatively charged components of 
the glycocalyx represent the first step towards cellular internalization (Amand et al. 2012; Li et al. 2013). In 
this respect, arginine proved to be particularly useful (Gasparini et al. 2015; Wender et al. 2008; Wexselblatt 
et al. 2014). However, charge alone is often insufficient to ensure efficient uptake since charge distribution, 
secondary structure and hydrophobicity also play important roles. For example, it was shown that 
macrocyclization of CPPs can improve cellular uptake  (Chu et al. 2015; Nischan et al. 2015; Qian et al. 2016; 
Upadhyaya et al. 2015). Hydrophobicity is integral to amphipathic CPPs and crucial for bilayer insertion and 
penetration, as hydrophobic amino acids (e.g. tryptophan) interact with the core of membranes (Gallivan et 
al. 1999; Persson et al. 1998; Regberg et al. 2014; Rydberg et al. 2012). Along those lines, lipidation can also 
favor the uptake of polar and amphipathic peptides (Lee et al. 2010; Mae et al. 2009; Nelson et al. 2007; Oh 
et al. 2014). It is important to note that the polar backbone largely contributes to the low cellular uptake of 
peptides. For that reason, several approaches were pursued to shield backbone amides. That involves 
N-methylation and the stabilization of certain peptide secondary structures that burry the 
backbone (Chatterjee et al. 2008; Chatterjee et al. 2013; Pelay-Gimeno et al. 2015). A particularly successful 
strategǇ represeŶts the staďilizatioŶ of α-helices (Azzarito et al. 2013), with hydrocarbon peptide stapling 
being among the most widely used approaches (Bird et al. 2016; Cromm et al. 2015). Overall, the structural 
diversity of CPPs complicates the identification of stringent rules that would allow a robust implementation 
of cell permeability (Brock 2014). This is a tremendous limitation for the design of peptide-derived inhibitors 
of intracellular proteins. 
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One particularly challenging intracellular target is β-catenin which regulates the Wnt signaling pathway 
via numerous PPIs. Wnt signaling governs substantial aspects of cell proliferation and differentiation and is 
involved in the onset and progression of numerous types of cancer. In colorectal cancer for example, 
hyperactive Wnt signaling occurs in more than 80% of all cases  (Chiurillo 2015; Muller et al. 2016). In most 
adult cells, the Wnt pathway is inactive and β-catenin is constantly degraded by the so-called destruction 
complex composed of the proteins Adenomatous polyposis coli (APC), Axin, casein kinase 1 (CK1α) and 
glycogen synthase kinase 3 (GSK3), among others. The destruction complex triggers phosphorylation and 
subsequent degradation of β-catenin. In healthy cells, activation of Wnt signaling is triggered by diffusible 
extracellular Wnt proteins which bind to the transmembrane receptor Frizzled (FZD) forming a complex with 
the low-density lipoprotein receptor-related protein 5/6 (LRP5/6). This leads to the recruitment of 
Dishevelled (Dvl) and Axin thereby blocking degradation of β-catenin. As a result, β-catenin accumulates and 
translocates into the nucleus where it triggers the formation of the transactivation complex leading to the 
transcription of Wnt target genes (Clevers et al. 2012). In an oncogenic context, hyperactivation of Wnt 
signaling is often triggered by a reduction of destruction complex activity, e.g. via mutations in APC, Axin or 
β-catenin itself, resulting in high levels of β-catenin (Polakis 2012). 
Approaches to inhibit Wnt signaling mainly involve the targeting of upstream pathway components: 
Transmembrane receptors have been inhibited with antibodies and peptidomimetics (Gurney et al. 2012; 
Jenei et al. 2009; Newnham et al. 2015; Safholm et al. 2008). Small molecules and macrocycles have been 
used to inhibit the segregation and maturation of Wnt ligands  (Chen et al. 2009; Liu et al. 2013; Madan et al. 
2016; Proffitt et al. 2013; Xu et al. 2017) and to target enzymes crucial for the function of the destruction 
complex (Chen et al. 2009; Huang et al. 2009; James et al. 2012; Thorne et al. 2010; Waaler et al. 2012). 
Since oncogenic mutations often occur in components of the destruction complex which is located in the 
center of the Wnt pathway, the usefulness of strategies targeting upstream components is limited. Inhibition 
of the transactivation complex (downstream in the pathway) would be insensitive to such mutations and is 
therefore considered an appealing anti-cancer strategy (Bertoldo et al. 2016; Emami et al. 2004; Gonsalves 
et al. 2011). Two stapled peptides have been reported to disrupt intracellular PPIs that involve β-catenin 
representing a first proof-of-concept (Grossmann et al. 2012; Takada et al. 2012). One of them is StAx 
(originally named StAx-35R) which targets the interaction between β-catenin and TCF/LEF transcription 
factors (Grossmann et al. 2012) but suffers from relatively low bioactivity presumably due to low cellular 
uptake. Herein we describe an integrative strategy to convey robust cellular uptake considering lessons 
learned from CPPs combined with the utilization of additional hydrophobic and positively charged 
modalities. This strategy yields a molecule with excellent cellular uptake showing high selectivity for 
β-catenin and very potent inhibition of proliferation and migration in intestinal cell-based assays. 
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RESULTS 
Comparison of cellular uptake 
Aiming for the installation of robust cell penetration of stapled peptide StAx, uptake properties of known cell 
penetrators were compared using five CPPs and one additional stapled peptide (SAHM1, Notch 
inhibitor (Moellering et al. 2009)). Among the CPPs, polycationic (Tat49-57, R8) as well as primary (Pep-1) and 
secondary (Penetratin) amphipathic sequences were selected (Figure 1A). For the assessment of cellular 
uptake, we used fluorescently labeled versions (f-, fluorescein) of these peptides. It is important to note that 
the quantitation of uptake is challenging as all established methods suffer from limitations. We decided to 
avoid techniques that require the fixation of cells as fixation tends to generate false positive results  (Richard 
et al. 2003), and chose a combination of fluorescence confocal microscopy and flow cytometry both 
employing live cells. Live cell confocal microscopy allows the subcellular localization of peptides but is not 
quantitative, while flow cytometry is quantitative but does not provide spatial information. 
 
Figure 1: Cell Permeability of CPPs and Stapled Peptides. (A) Peptide classes known to penetrate cells including examples 
(for peptide sequences see Table S2). Net charge of peptides is given (calculated with property calculator by Innovagen AB). 
(B) Plot of geometric mean fluorescence intensities (mFI) obtained by flow cytometry (10,000 events of live cells, at least 
three independent biological replicates, error bars represeŶt ϭσͿ. HeLa cells were treated with FITC-labeled peptides (5 µM, 
90 min). (C) Live cell confocal fluorescence microscopy of HeLa cells incubated with FITC-labeled peptides (5 µM, 90 min). 
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For flow cytometry experiments, HeLa cells were incubated with labeled peptides (5 µM, 90 min), then 
stringently washed and treated with protease to remove cell-surface bound peptides. The mean 
fluorescence intensity (mFI) of analyzed cells reveals for all peptides higher uptake than for the fluorescent 
label (fluorescein) alone (Figure 1B). Within this panel, primary amphipathic peptide Pep-1 and stapled 
peptide SAHM1 convey in highest fluorescence intensities, while polycationic peptides (Tat, R8) and 
secondary amphipathic peptide Penetratin show considerably lower uptake. Interestingly, the uptake of StAx 
is also in this range and about 7-fold lower than the one of Pep-1 and SAHM1. Using confocal microscopy, we 
examined the subcellular localization revealing for all peptides (though to a varying extent) cytosolic and 
nuclear distribution as well as accumulation in intracellular vesicular structures presumably 
endosomes  (Brock 2014) (Figure 1C). SAHM1, Pep-1 and R8 exhibit a comparably high cytosolic fraction 
while StAx and Penetratin show predominantly vesicular localization. Taken together, stapled peptide 
SAHM1 and CPP Pep-1 combine cytosolic distribution (microscopy) with high overall uptake (flow 
cytometry). StAx is only moderately internalized and shows low cytosolic distribution which is similar to the 
behavior of Tat and Penetratin. Considering StAǆ’ positive net charge (+5.1), stabilized helical conformation 
and hydrophobic character, it already possesses fundamental features for uptake explaining its basic cell 
permeability. To increase cellular uptake and ensure robust bioactivity, we applied a strategy that on the one 
hand aims at fine tuning of core sequence hydrophobicity, and on the other hand explores a variety of N-
terminal modifications to introduce additional hydrophobic or polar groups. 
Variation of Stapled Peptide StAx 
StAx (Figure 2A) was previously optimized for high target affinity and to incorporate the maximum number 
of arginines (R) that were compatible with target binding. As a result, there was little potential for additional 
variations to be made to the core peptide sequence (Figure 2A). Knowing that the six arginine residues in 
StAǆ do Ŷot sigŶifiĐaŶtlǇ ĐoŶtriďute to β-catenin binding, we considered the modification of these sites. Since 
the positively charged guanidinium group is crucial for cell penetration, we focused on the modulation of its 
alkyl chain aiming at increasing its hydrophobic character, a strategy that has already proven useful for the 
improvement of CPPs (Wender et al. 2000). For that reason, arginine derivatives with altered linker 
structures namely homo-arginine (hR, longer alkyl linker) and 4-guanidino-phenylalanine (pR, aromatic 
linker) were incorporated instead of the natural amino acid (Figure 2B). In the two new resulting peptides, all 
arginines were replaced either by hR (StAx-h) or by pR (StAx-p). In fluorescence polarization (FP) assays, we 
verified that peptides f-StAx-p and f-StAx-h exhibit an affinity for recombinant full length β-catenin (Kd = 66 
and 123 nM, respectively) that is in the range of the original StAx peptide (Kd = 108 nM, Figure S1). 
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Figure 2: StAx peptide derivatives inhibit Wnt reporter gene activity. (A) StAx sequence with schematic representation of its 
bioactive secondary structure (derived from crystal structure of a related StAx-deriǀatiǀe iŶ Đoŵpleǆ ǁith β-catenin, PDB: 
4DJS). (B) Chemical structure of homo-arginine (hR) and 4-guanidino-phenylalanine (pR). (C) Groups that were employed for 
N-terminal modification of peptides. (D) Heat map representation of inhibition of Wnt signaling activity (for IC50-values see 
Figure S2) in a Wnt reporter gene assay (293T cells were transfected with: i) Wnt3a-expressing vector, ii) vector with Super 
(8x)TOPFlash involving TCF-responsive firefly luciferase and iii) vector with Renilla luciferase control). After peptide treatment 
(22 h), luciferase signal was detected (* highest activity within the panel). Experiments were performed at least as two 
independent biological replicates (each with three technical replicates, for details see STAR Methods and Figure S2). 
 
Based on these three core sequences, we selected a diverse set of N-terminal modifications (Figure 2C). 
Attachment of different hydrophobic moieties including acetylation (Ac-), capronylation (C6) and 
palmitoylation (C16-) stepwise increases hydrophobicity and presumably affinities for membranes. In 
addition, we investigated hydrophilic modalities involving the free N-terminus (H2N-) and Spermine (sp-) as 
well as the nuclear localization sequence (NLS-) of SV40 large T-antigen. This NLS peptide sequence contains 
four lysines and one arginine (Figure 2C) and was previously used to improve both cellular uptake and 
nuclear localization (Ragin et al. 2002). The latter is an aspect which may also support biological activity of 
StAx peptides since the target protein complex is enriched in the nucleus (Cadigan et al. 2012).  
The resulting 21 peptides (including fluorescently labeled versions) were synthesized and tested regarding 
their potential to inhibit canonical Wnt signaling in a cell-based assay. For that purpose, 293T cells were 
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transfected with two vectors: One with 7 tandem repeats of a TCF/LEF response element (including 
minimum promoter) upstream of firefly luciferase (TOPflash), and another one with Renilla luciferase for 
normalization (Lanier et al. 2012). Wnt signaling was activated in an autocrine and paracrine fashion by co-
transfection with a third vector expressing the Wnt3A ligand. Cells were incubated with varying peptide 
concentrations (0.1–10 µM) and luciferase activity was measured after 22 h. Corresponding half maximal 
inhibitory concentrations (IC50) were determined. For assay validation, we tested the known Wnt inhibitor 
XAV939 acting upstream in the signaling pathway which shows inhibition in the expected activity range 
(IC50 = 0.07 µM, Figure S2). Our peptide panel shows diverse inhibitory effects (Figure 2D) but importantly no 
general toxicity within the tested dose range (based on Renilla luciferase). Among the three core sequences, 
StAx-h harboring six homo-arginine residues shows highest Wnt pathway inhibition. Within the StAx-h series, 
small and/or hydrophilic modifications result in highest activities with H2N- and NLS- being the most active 
ones (IC50 = 1.4 µM).  
 
StAx-h peptides are efficient cell penetrators 
Knowing that the three core sequences (StAx, StAx-p, StAx-hͿ shoǁ siŵilar affiŶitǇ for β-catenin (Figure S1), 
we suspected that differences in inhibitory activity originate from differences in cellular uptake and 
distribution. To test this hypothesis, cell penetration was investigated by flow cytometry and microscopy 
employing fluorescently labeled versions of the three core peptides (f-StAx, f-StAx-p, f-StAx-h). In addition, 
fluorescently labeled NLS-modified StAx-h (f-NLS-StAx-h) was included as it showed highest activity in the 
reporter gene assay (together with H2N-StAx-h). Flow cytometry-based readout of cellular uptake was 
performed using a dilution series of peptides (0.1‒5 µM, 90 min, Figure 3A). Overall, uptake increases with 
peptide concentration (though to a varying extent) with all variants showing improved penetration when 
compared to the original StAx peptide (black). Interestingly, f-NLS-StAx-h exhibits the largest increase (7-fold 
at 5 µM) with respect to StAx placing it in the range of the best CPPs (mFI at 5 µM: 17.0 for f-NLS-StAx-h, 16.4 
for Pep-1, Figure 1B). Subsequently, life cell confocal microscopy was performed (5 µM, 90 min, Figure 3B) to 
investigate the subcellular localization of all four peptides. Peptide f-StAx-p is predominantly membrane 
associated (Figure 3B) presumably do the strong hydrophobic character of the aromatic moiety in pR. In 
contrast, the two StAx-h derivatives show considerable cytosolic distribution which is particularly 
pronounced for f-NLS-StAx-h (Figure 3B).  
 
8 
 
Figure 3: Cellular Uptake of selected StAx peptides. (A) Plot of geometric mean fluorescence intensities (mFI) obtained by 
flow cytometry (10,000 events of live cells, at least three iŶdepeŶdeŶt ďiologiĐal repliĐates, error ďars represeŶt ϭσͿ. HeLa 
cells were treated with fluorescently-labeled peptides (0.1–5 µM, 90 min). (B) Live cell confocal fluorescence microscopy 
depicting HeLa cells incubated with fluorescently-labeled peptides (5 µM, 90 min). For details see STAR Methods. 
 
StAx-h binds β-catenin and inhibits Wnt target gene expression 
Taken together, Wnt reporter activity (Figure 2D) and cell permeability (Figure 3) indicate that core sequence 
StAx-h holds the highest potential for efficient inhibition of Wnt signaling. Before investigating StAx-h 
poteŶĐǇ iŶ detail, ǁe aiŵed for the ǀalidatioŶ of its ďiŶdiŶg to β-catenin in a cellular context. For that 
purpose, pull-down experiments were performed using a biotinylated version of StAx-h (b-StAx-h). The 
peptide was immobilized on Streptavidin beads and incubated with the lysate of DLD-1 cells, a colon cancer 
cell line ǁith eleǀated β-catenin levels. After stringent washing, bound proteins were subjected to tryptic 
digestion and fragments analyzed by HPLC-coupled high-resolution mass spectrometry. Identified proteins 
were plotted in accordance to their enrichment and statistical relevance compared to pull-down with beads 
only. The resulting volcano plot (Figure 4A) shows 37 proteins that are significantly enriched ǁith β-catenin 
being one of the highest scoring ones (orange, Figure 4A). Most strikingly, among the remaining 36 proteins, 
17 are proposed ĐoŵpoŶeŶts of β-catenin containing complexes (blue, Figure 4A, for complete list see Table 
S3) supporting selective binding of StAx-h to β-catenin. Most of these potential complex partners are either 
involved in transcriptional activator complexes (e.g. RUVBL1 and RUVBL2) or cell-cell adhesion junctions (e.g. 
α-catenin and E-cadherin). 
Having verified StAx-h as β-catenin binder, we investigated its effects on the expression of Wnt target 
genes using mouse-derived small intestinal crypt organoids expressing a doxycycline(dox)-inducible and 
stable form of β-catenin (activated β-catenin) (Dale et al. 2015; Jarde et al. 2013). Importantly, removal of 
dox (-dox, Figure 4B) results iŶ loss of aĐtiǀated β-catenin thereby reducing the mRNA level of Wnt target 
genes (e.g. Axin2, Myc, Ascl2, Tiam1) and increasing levels of differentiation marker Car4. Notably, treatment 
with H2N-StAx-h (Figure S3) or NLS-StAx-h (Figure 4B) results in gene expression changes consistent with 
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inhibition of Wnt signaling following loss of activated β-catenin resulting from doxycycline removal (‒dox, 
Figure 4B). For NLS-StAx-h, this effect is observed as early as 2 h after initiation of treatment and plateaus 
after ca. 6 h ǁith ŵRNA leǀels iŶ the raŶge of the ĐoŶtrol saŵple laĐkiŶg aĐtiǀated β-catenin expression. As 
an additional control, StAx-h-derived peptide StCo (for sequence see Table S2) was designed that shows 
greatlǇ diŵiŶished affiŶitǇ for β-catenin (Kd ~ 10 µM, Figure S1) due to the substitution of three amino acids 
direĐtlǇ iŶǀolǀed iŶ β-catenin binding. Importantly, the NLS-modified version of this peptide (NLS-StCo) does 
not alter the level of investigated Wnt-responsive target genes (Figure 4B). 
 
 
Figure 4: Wnt-pathway selectivity of StAx-h peptides. (A) Volcano plot of pull-down with biotinylated StAx-h (b-StAx-h) 
which was immobilized on streptavidin-coated beads and incubated with DLD-ϭ Đell lǇsate ;ϯ hͿ. β-catenin (orange) and 
sigŶifiĐaŶtlǇ eŶriĐhed kŶoǁŶ ďiŶdiŶg partŶers iŶ β-catenin-containing complexes (blue) are highlighted (for complete list of 
pull-down results see Table S3). (B) Target gene expression in small intestinal colon crypt organoids expressing a dox-
iŶduĐiďle ŵutaŶt β-catenin (Tet-O-Δϭ-89-β-catenin). Level are plotted relative to dox-induced cells (+dox) lacking peptide 
treatment. Organoids induced with 4 µg/mL dox were treated with 10 µM NLS-StAx-h or NLS-StCo (for sequence see Table 
S2). mRNA level of Wnt target genes (Myc, Ascl2, Tiam1 or Axin2), and of differentiation marker Car4 were quantified. Gene 
expression changes as a result of removal of doǆ for the last Ϯϰ h ;‒doǆͿ are shown on the left. Experiments were performed 
as three independent biological replicates, each with three technical replicates. Values in all bar graphics depict mean values 
aŶd error ďars represeŶt ϭσ. *p < 0.05, ns = not significant. 
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NLS-StAx-h Inhibits Proliferation and Migration of Colorectal Cancer Cells 
Inhibition of Wnt signaling reduces growth of Wnt-dependent cancer cell lines but has no effect on cells that 
grow independent of Wnt signaling. To test activity and specificity of StAx-h peptides, cancer cell lines 
originating from different human tissues were screened for their sensitivity towards inhibitor treatment. This 
involves Wnt-addicted colon cancer cell lines DLD-1 and SW-480 in which the Wnt-pathway is activated via 
truncations of the destruction complex component APC. In addition, we chose cell lines that are reported to 
be Wnt-independent: U87 glioblastoma cells, MCF-7 breast cancer cells and U2OS osteosarcoma 
cells (Forbes et al. 2015). Viability read-out was performed via quantitation of cellular ATP levels. Compared 
to previous studies, inhibitors (c = 10 µM) were tested under stringent conditions using normal serum 
concentration (rather than starving conditions) (Huang et al. 2009) and a relatively short incubation time of 
72 h (compared to 5‒6 d) (Chen et al. 2009; Fujii et al. 2007; Grossmann et al. 2012). Under these conditions, 
original peptide Ac-StAx and known Axin stabilizer XAV939 do not show significant effects on the viability of 
Wnt-addicted DLD-1 and SW-480 cells. The two peptides performing best in the reporter gene assay (H2N-
StAx-h and NLS-StAx-h) were also tested. H2N-StAx-h only shows a moderate effect on SW-480 cells (38 % 
inhibition) while most cell penetrating stapled peptide NLS-StAx-h reduces viability of both SW-480 and 
DLD-1 by more than 80 % (Figure 5A). Control peptide NLS-StCo, lacking affinity for β-catenin, does not have 
an effect on viability. As expected, none of the StAx-derived peptides inhibits growth of Wnt-independent 
cell lines (U87, U2OS and MCF7, Figure 5A). Interestingly, XAV939 shows some effect on the viability of MFC7 
cells (48 % inhibition) indicating some activity that is independent from inhibition of Wnt signaling. 
Having studied the cellular uptake of fluorescently labeled StAx-derivatives in detail, we also tested their 
effect on viability (Figure S4). In line with the reporter gene assay and its relatively low cellular uptake, 
f-StAx-h shows very low activity on Wnt-dependent SW-480 cells. For f-NLS-StAx-h, we observe activity in the 
range of the non-labeled version indicating comparable cellular uptake. Interestingly, both fluorescently 
labeled peptides (f-StAx-h and f-NLS-StAx-h) cause ca. 20% reduction of viability for Wnt-independent MFC-7 
cells (Figure S4) indicating non-specific toxicity caused by the fluorescein label. Notably, the most active 
peptide (NLS-StAx-h) harbors a nuclear localization signal which apparently does not result in nuclear 
accumulation (Figure 3B). For that reason, we were interested if its high cellular activity is predominantly 
caused by high cellular uptake due to the five positively charged NLS side chains. For that purpose, a charge 
analog harboring five N-terminal lysine residues instead of the NLS (KKKKK-StAx-h) was designed. And 
indeed, KKKKK-StAx-h reduces the viability of Wnt-addicted SW-480 similar to NLS-StAx-h while not affecting 
Wnt-independent MCF-7 cells. In line with this observation, the overall cellular uptake of f-KKKKK-StAx-h is 
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only slightly lower than that of f-NLS-StAx-h (mFI at 5 µM: 13.9 vs. 17.0, Figure S5) indicating that the high 
cellular activity of the NLS-modified version is mainly triggered by increased cellular uptake supported by 
positive charges within the NLS. 
 
Figure 5: NLS-StAx-h inhibits cell proliferation and migration. (A) Viability assay of Wnt-addicted (SW-480, DLD-1) and Wnt-
independent cell lines (U87, U2OS, MCF-7) after treatment with compound (10 µM, 72 h). Viability is plotted relative to 
DMSO treated cells. (B) Wound-closure assay of DLD-1 cells. For 24 h, cells were treated with either DMSO or peptide at 
given concentration (grey: initial cell area, blue: initial wound, orange line: front of cells after 24 h. (C) Wound closure of 
experiment in Figure 5B was quantified. Experiments were performed as three independent biological replicates, each with 
three technical replicates. (D) Time-dependent wound-closure assay comparing treatment with NLS-StAx-h (orange) and 
control peptide NLS-StCo (blue). Experiments were performed as three independent biological replicates, each with three 
technical replicates. Values in all bar graphiĐs depiĐt ŵeaŶ ǀalues aŶd error ďars represeŶt ϭσ. *p < 0.05, **p < 0.01, 
***p < 0.001, ns = not significant). 
 
The active Wnt pathway not only supports cell proliferation, but also cell migration which crucially 
contributes to cancer metastasis (Iskit et al. 2015; Li et al. 2011; Sack et al. 2011). Thus, most active peptide 
12 
NLS-StAx-h and control peptide NLS-StCo were tested in a wound-closure assay using DLD-1 cells. After 
introduction of a sterile wound (blue, Figure 5B), cells were treated either with DMSO or with one of the 
peptides for 24 h. In absence of peptide (DMSO), the original wound was already closed by 69 % after 24 h, 
while NLS-StAx-h treatment resulted in dose-dependent inhibition of this process (wound closure: 52 % at 
5 µM, and 24 % at 10 µM, Figure 5B and C). As expected, NLS-StCo (10 µM) shows no inhibitory effect. This 
robust inhibition of cell migration, was confirmed by time-dependent measurements (Figure 5D) revealing 
significant inhibition of wound-closure as early as 5 h after initiation of treatment. As an additional control, 
we performed the wound-closure assay with Wnt-independent MCF-7 cells. Importantly, these cells were 
not affected by NLS-StAx-h treatment (Figure S6). Together with the inactivity of control peptide NLS-StCo, 
this indicates that indeed Wnt-inhibition is responsible for observed effects on the migration of DLD-1 cells.  
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DISCUSSION 
Previously we reported a stapled peptide (StAx) that targets β-catenin, the central hub in canonical Wnt-
signaling, but its activity suffers from low cellular uptake. Even though there is some rational, it is not 
possible to design highly cell permeable and bioactive stapled peptides from scratch (Bird et al. 2016; Chu et 
al. 2015; Cromm et al. 2016). It is known that some features appear to be necessary (but not sufficient) for 
efficient uptake of positively charged peptides: (a) A certain degree of hydrophobicity, and (b) A spatially 
separated hydrophobic and cationic stretch. Presumably, this is due to a two-step uptake mechanism that 
initially involves interaction of cationic peptide groups with negatively charged membrane components 
which is followed by insertion of hydrophobic residues into the membrane core.  
To evaluate cell permeability of StAx, we compared its cellular uptake and localization with known CPPs 
(5 µM, 90 min, HeLa cells). Interestingly, StAx uptake is in the range of first generation CPPs such as Tat but 
about 7-times lower than best performing peptides Pep-1 and SAHM1. StAx already has a number of 
hydrophobic and positively charged amino acids, however, they are spatially not separated. Since there is 
only little room for a variation of the StAx core sequence, we decided to pursue a strategy that considers 
minor sequence alterations (derivatization of existing arginines) and a set of hydrophobic and polar N-
terminal modifications (including an NLS). At this point, it was not clear whether uptake would be supported 
by additional cationic or hydrophobic groups. After validating that arginine derivatization does not interfere 
ǁith β-catenin binding, a small library consisting of 21 modified peptides was synthesized and tested 
regarding their activity in a Wnt-dependent reporter gene assay. This assay showed that polar N-terminal 
modifications in combination with a slightly more hydrophobic core sequence (homo-arginine instead of 
arginine) provide most active peptides. While activity trends observed for the reporter gene assay are in line 
with growth inhibition, the dynamic range in the reporter gene assay is smaller. This behavior can be due to 
the non-physiological concentration and activity of the promotor used in the reporter gene assay, and it 
highlights the importance of more relevant secondary cell-based assays for hit validation. Analysis of cell 
permeability revealed that in particular the analogue with an N-terminal NLS sequence (NLS-StAx-h) shows 
very high cellular uptake and cytosolic distribution comparable to best cell penetrators Pep-1 and SAHM1. 
Interestingly, a charge analog bearing five lysine residues instead of the NLS shows similar cellular uptake 
indicating that the basic character of the NLS is of central importance.  
Having an active aŶd Đell perŵeaďle peptide aǀailaďle, ǁe ǁere iŶterested if the peptide iŶdeed targets β-
catenin in a cellular context. To address this question, pull-down experiments were performed using a 
biotinylated StAx-h peptide and analyzed with high-resolution MS. In this assay, β-catenin and some of its 
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kŶoǁŶ ďiŶdiŶg partŶers ǁere sigŶifiĐaŶtlǇ eŶriĐhed ǀerifǇiŶg β-catenin binding. Notably, we did not identify 
any of the LEF/TCF transcription factors which is expected since they compete with StAx-h for β-catenin 
binding. Analysis of changes in the transcription of Wnt-target genes in mouse-derived small intestinal crypts 
unambiguously shows inhibition of Wnt signaling after treatment with StAx-h. Importantly, an NLS-StAx-h 
derived control peptide (NLS-StCo) does not affect mRNA level of these genes.    
In a number of cancer cells types, expression of Wnt-target genes is essential for cell proliferation and 
migration which are crucial for the oncogenicity of these cells. Consequently, selective inhibition of Wnt-
signaling is considered an appealing anti-cancer strategy. In this respect, it is important to note that 
oncogenic mutations that lead to hyperactive Wnt-signaling are often found downstream (right Figure 6), i.e. 
at the level of the destruction complex (e.g. in APC) or iŶ β-catenin itself. For that reason, inhibitors that act 
on upstream pathway components involved in Wnt biosynthesis, membrane signal transduction or 
regulation of the destruction complex (left, Figure 6) are of limited therapeutic use in such a context. This 
reŶders iŶhiďitors of the doǁŶstreaŵ iŶteraĐtioŶ ďetǁeeŶ β-catenin and LEF/TCF transcription factors, such 
as NLS-StAx-h, interesting tool compounds to test the potential of this targeting strategy.  
 
 
Figure 6: Oncogenic activation of Wnt signaling via APC truncation. Schematic representation of the Wnt pathway activated 
either regularly via diffusible Wnt ligands (left), or oncogenically via truncation of APC (right). 
 
To investigate the potency and specificity of NLS-StAx-h, we tested its impact on the viability of Wnt-
dependent and -independent cell lines. Applying stringent assay conditions (high serum concentration and 
relatively short incubation times), we observed inhibition of proliferation (80% inhibition after 72 h) and 
migration (2.8-fold reduced wound-closure after 24 h) only for Wnt-dependent cell lines. Importantly, 
activity of NLS-StAx-h exceeds that of known Wnt inhibitor XAV939 which stabilizes a component of the 
destruction complex and does not show inhibition of cell proliferation under our stringent conditions. The 
same holds true for starting peptide StAx which highlights the importance of robust cellular uptake for high 
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activity. Interestingly, published small molecule inhibitors of downstream Wnt-signaling are required to be 
applied at higher concentrations (iCRT3: 75 µM, ICG-001: 25µM vs. NLS-StAx-h: 10 µM) to interfere with cell 
proliferation (Emami et al. 2004; Gonsalves et al. 2011). Given the inherent difficulties associated with 
peptide uptake, this is highly remarkable and highlights the significance of our optimization strategy as well 
as the importance of NLS-StAx-h for the future investigation of approaches that target the Wnt 
transactivation complex. 
 
SIGNIFICANCE 
The development of highly cell permeable and bioactive peptides is extremely challenging and represents 
the bottleneck for an application of peptide-derived molecules. The strategy reported herein allowed the 
implementation of robust cell permeability using a stapled peptide with low cellular uptake as starting point. 
Importantly, this approach should be applicable to a multitude of peptide-derived inhibitors that suffer from 
low uptake. Herein described stapled peptide NLS-StAx-h inhibits oncogenic Wnt signaling which is a driver in 
numerous types of cancer, in particular in colorectal cancer (CRC). CRC is the third most common cancer in 
men and the second most common cancer in women. The overall survival rate is as low as 8.5% and 
highlights the need for novel and efficient therapies. Aiming for the inhibition of intracellular pathway 
components, small molecules have been developed mainly targeting enzymes that are involved in multiple 
signaling pathways which holds the risk of undesired side effects. The development of novel targeting 
strategies is complicated since Wnt signaling is regulated by numerous PPIs which proved reluctant to 
inhibition by small molecules. NLS-StAx-h iŶhiďits the iŶteraĐtioŶ ďetǁeeŶ β-catenin and corresponding 
transcription factors targeting the very end of the Wnt pathway. Importantly, this is the first compound that 
ĐoŵďiŶes good Đellular uptake ǁith effiĐieŶt iŶhiďitioŶ of β-ĐateŶiŶ‒traŶsĐriptioŶ faĐtor iŶteraĐtioŶs. These 
features render NLS-StAx-h an extremely potent and selective Wnt inhibitor thereby providing a highly 
valuable pharmacological tool for the investigation of a targeting approach that acts on downstream 
components of the pathway for cancer treatment.  
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the 
Lead Contact, Tom N. Grossmann (t.n.grossmann@vu.nl). 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Bacterial Strains 
For expression of human full-leŶgth β-catenin Escherichia coli (E. coli) strain BL21-GOLD(DE3) was used and 
cultured in TB medium. 
Cell Lines 
The cell lines SW-480 and 293T were obtained from Deutsche Sammlung von Mikroorganismen und 
Zellkulturen (DSMZ) and the DLD-1 cell lines was purchased from the American Type Culture Collection 
(ATCC). HeLa, U87, MCF-7 and U2OS cell lines were kindly provided by Max Planck Institute of Molecular 
Physiology, Dortmund, Germany. Hek293T, HeLa, U87, MCF-7, U2OS were cultured in DMEM supplemented 
with 10% fetal calf serum, stable L-glutamine and 1x non-essential amino acids). DLD-1 and SW-480 were 
maintained in RPMI-1640 supplemented with 10% fetal calf serum and L-glutamine. Cultures were 
maintained at 37 °C in a humidified atmosphere of 5% CO2.  
Mice 
The Tet-O-β-catenin line mice had both the Tet-O-β-catenin allele and the ROSA26-M2-rtTA allele and were a 
mixed SV129 x C57Bl/6 background  (Jarde et al. 2013). The small intestinal organoids used for the assays 
were obtained from a 4-ŵoŶth old ŵale. The ĐoloŶǇ ǁas ďred aŶd ŵaiŶtaiŶed iŶ ĐoŵpliaŶĐe ǁith the UK’s 
Animal (Scientific Procedures) Act under project license 30/3279 in filter top cages in a specific pathogen free 
facility under 12 h light/12 h dark conditions. Water and food were provided ad libitum.  
 
METHOD DETAILS 
Peptide Synthesis 
Peptides were synthesized following standard Fmoc-protocols for solid-phase peptide synthesis (Kim et al. 
2011). Abbreviations for used chemicals can be found in Table S1. Peptide synthesis was performed on Rink 
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amide NovaSyn®TGR (Merck) or ChemMatrix® resin (Sigma-Aldrich). Amino acids were dissolved in DMF 
including 0.5 M OxymaPure® and coupled twice or three times. For coupling, amino acids were mixed with 
3.9 eq of HCTU and 8 eq of DIPEA in DMF and added to the resin for 40 min. After amino acid coupling, the 
remaining free amino groups were blocked with NMP/acetic anhydride/DIPEA (10/1/1) for 2 min. Fmoc-
deprotection was performed with 25 % piperidine in NMP for 10 min. 
Crosslinking of unnatural olefinic amino acids (Okeanos Tech) was performed by ring closing metathesis 
(RCM). The dried resin was swollen in DCE for 30 min. A solution of Grubbs 1
st
 generation catalyst 
(4 ŵg∙ŵL-1) in DCE was added to the resin and reacted for 1 h at room temperature. During reaction, 
nitrogen was bubbled through the mixture. The procedure was repeated five times and the resin was 
washed in a DMSO/DCM (1/1) solution for 10 min followed by a washing step in DCM.  
To obtain a free N-terminus, peptides were deprotected with 25 % piperidine in NMP for 10 min. For 
acetylation, the last Fmoc-protecting group was removed and the free N-terminus was reacted twice with 
capping solution. Lipid and spermine modification were obtained through coupling of 4 eq of hexanoic acid, 
hexadecanoic acid or FBBSuc-OH using 3.9 eq PyBOP and 8 eq DIPEA. Fmoc-O2Oc-OH was coupled as a 
spacer to peptides subjected to FITC or NLS modification. FITC-labelling was performed twice with a 4-fold 
excess of FITC and 8 eq. DIPEA in NMP for 1 h. NLS was coupled according to the general SPPS protocol. 
Before biotinylation, Fmoc-NH-PEG(5)-COOH was introduced N-terminally using 3.9 eq PyBOP and 8 eq 
DIPEA. D-Biotin was coupled twice using PyBOP and DIPEA. 
Peptides were cleaved from the resin with TFA/H2O/TIPS (95/2.5/2.5) for 4 h and precipitated with diethyl 
ether at -20°C. Semi preparative HPLC was carried out on a LC-8A system (Shimadzu) using a Nucleodur C18 
reverse-phase column (10 x 125 mm, particle size 5 µm, Macherey-Nagel; solvent A: water + 0.1 % TFA; 
solvent B: acetonitrile + 0.1 % TFA; flow rate: 6 ŵL∙ŵiŶ-1). Products were characterized on an analytical 1260 
Infinity HPLC/ESI system (Agilent Technologies) equipped with a Zorbax C18 reverse-phase column (4.6 x 
150 mm, particle size 5 µm, Agilent Technologies; solvent A: water + 0.1 % TFA; solvent B: acetonitrile + 
0.1 % TFA; flow rate: 1 ŵL∙ŵiŶ-1). High-resolution mass spectra were recorded on a QLT Orbitrap mass 
spectrometer coupled to an Accela HPLC-System (HPLC column: Hypersyl GOLD, 50 mm x 1 mm particle size 
1.9 µm, ionization method: Electrospray Ionization). Analytical data are shown in Supporting Table S2. 
According to Lambert-Beer law, yields were quantified by UV absorbance at 280 nm with an extinction 
coefficient of 11,000 M
-1∙cm-1 (StAx) or 5,500 M-1∙cm-1 (StCo). FITC-labeled peptides were measured at 
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495 nm in 100 mM sodium phosphate buffer (pH 8.5) and calculated with an extinction coefficient of 
77.000 M
-1∙cm-1. 
β-catenin Expression and Purification 
E. coli BL21-Gold(DE3) cells (Agilent Technologies) were transformed with a modified pET-28a(+) plasmid 
engineered to harbour a C-terminal hexahistidine-tag and PreScission cleavage site after the full-leŶgth β-
catenin gene. The gene coding for the full-leŶgth β-catenin protein is based on Genbank entry NM_001904.3. 
The fragment was obtained through gene synthesis (Integrated DNA Technologies). TB medium was 
inoculated with an overnight culture and incubated at 37° C until it reached an optical density of 1 at a 
wavelength of 600 nm. Protein expression was induced with 0.4 mM IPTG and incubated overnight at 18 °C. 
The harvested cell pellet was resuspended in a lysis buffer containing 50 mM Tris pH8.0, 300 mM NaCl, 1 mM 
β-mercaptoethanol, 5 % glǇĐerol aŶd ĐOŵplete™, EDTA-free Protease Inhibitor Cocktail (Roche) and 
disrupted with a microfluidizer. Cell debris was removed through centrifugation at 70.000 rcf, 4 °C for 
40 ŵiŶ. β-ĐateŶiŶ ǁas isolated froŵ the lǇsate ďǇ affiŶitǇ ĐhroŵatographǇ ;His Trap™ HP, GE HealthĐareͿ. 
The N-terminal His-tag was not cleaved. The protein was eluted with an imidazole containing buffer (50 mM 
Tris pH8.0, 300 mM NaCl, 1 ŵM β-mercaptoethanol, 5 % glycerol and 250 mM imidazole). Further impurities 
were removed through size exclusion chromatography (20 mM Tris pH 8.0, 150 mM NaCl, 5 ŵM β-
mercaptoethanol, 10 % glycerol; Column: HiLoad 16/600 Superdex 200, GE Healthcare). The protein solution 
was concentrated by ultrafiltration and was always used fresh in experiments. 
Fluorescence Polarization Assay  
β-Catenin was serially diluted in black, small volume, flat-bottom, non-binding 384-well plates (Greiner) in 
size exclusion buffer containing 0.05 % Tween 20 (FP buffer). 0.1 mM DMSO stock solutions of FITC-labeled 
peptides were dissolved in FP buffer to a 40 nM solution. Diluted peptides were then added to the protein 
and give a final concentration of 10 nM. After incubation for 1 h at 4 °C, the increase in fluorescence 
polarizatioŶ of the fluoresĐeŶtlǇ laďeled ligaŶd ǁas reĐorded ;SafireϮ, TeĐaŶͿ ǁith λ;eǆͿ = 470 nm and 
λ(em) = 525 nm. Kd-values were determined by nonlinear regression analysis of dose-response curves (four 
parameters, variable slope) using GraphPad Prism 5 software (version 5.03). 
Flow Cytometry  
5x10
4
 HeLa cells were plated in 24-well plates and allowed to grow 24 h in complete growth medium (DMEM 
supplemented with 10 % fetal calf serum, L-glutamine and non-essential amino acids). DMEM was carefully 
aspirated and cells were treated with fresh pre-warmed complete growth medium supplemented with 5 µM 
of peptide at a final concentration of 0.5 % DMSO or vehicle control only. After 90 min incubation, cells were 
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washed three times in PBS and treated for 3 min with 0.25% Trypsin/0.02% EDTA in PBS solution (PAN 
Biotech). The dissociation reaction was stopped using complete growth medium. Cells were then harvested 
through centrifugation (3 min, 180 g) and washed additional three times in PBS. Cells were then resuspended 
in 500 µL PBS and strained through a cell strainer cap into a 5 mL round-bottom tube (Falcon). Cells were 
subjected to a LSRII flow cytometer (BD). Using forward and side scattered light, a gate for intact, non-
aggregated cells was defined. To obtain a statistical relevant population, the fluorescence at 530 nm of 
10,000 events was collected within this cell gate (filter: 530/30, mirror: 502 LP). Data was analyzed using 
FlowJo software (version 10.1) and results were shown as geometric means of fluorescence collected at 
530 nm.  
Confocal Microscopy 
1.5x10
5
 HeLa cells were plated on 35 mm glass bottom dishes (MatTek) and cultured for 24 h in complete 
growth medium (DMEM supplemented with 10 % fetal calf serum, L-glutamine and non-essential amino 
acids). Then, DMEM was carefully aspirated and cells were treated with fresh pre-warmed complete growth 
medium supplemented with 5 µM peptide at a final concentration of 0.5 % DMSO or DMSO vehicle control. 
After 90 min treatment, cells were washed three times in warm PBS to remove excess peptide from the cell 
surface and left in pre-warmed imaging medium (PAN Biotech). Cells were immediately analyzed under a 
LSM510 meta confocal microscope (Zeiss) in a pre-warmed incubation chamber (37°C). By scanning through 
the z-planes of each cell, the outer plasma membrane borders were determined. Images were taken 
between the plasma membrane z-planes to obtain signals from internalized peptides and to minimize 
artificial signals from cell surface adhered peptides. Fluorescence was excited using a 488 nm argon laser 
(filter:505-540 BP). The distribution of FITC-labeled peptides was analyzed using a 63x Plan-Apochromat oil 
objective (Zeiss).  
Dual Luciferase Reporter Gene Assay 
Inhibitory potency of StAx peptides was tested with 293T cells in a 96-ǁell forŵat WŶtϯa/β-catenin 
luciferase reporter gene assay (Lanier et al. 2012). HEK293T cells were cultured in DMEM supplemented with 
10 % FCS at 37 °C in 5 % CO2. For transient transfection, Lipofectamine®2000 (Thermo Fisher) and the 
appropriated plasmids were pre-incubated in Opti-MEM® medium for 15 min at room temperature. To cover 
a 96-well plate, 3x10
6
 cells were transiently transfected with Wnt3A-expressing vector for pathway 
activation, together with the commercially available Super(8x)TOPflash reporter vector harboring a (7×)TCF-
firefly luciferase response element and the TK-driven Renilla luciferase co-reporter vector, as an internal 
transfection control to normalize the luminescence, and again incubated at 37 °C in 5 % CO2 . After 8 h, cells 
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were harvested and counted. 25,000 transfected cells were seeded in 110 µL Media per well. Cells were 
allowed to adhere for 1 h. Cells were treated either with 10 µL of peptide solutions in different 
concentrations (final concentration 10, 5, 2.5, 1, 0.5, 0.25, 0.1 µM with 0.5 % DMSO), untreated and DMSO 
(0.5 %)-treated negative vehicle controls. After 22 h incubation, the medium was carefully aspirated. 
AĐĐordiŶg to the ŵaŶufaĐturer’s protoĐol, Đells ǁere theŶ lǇsed iŶ lǇsis ďuffer folloǁed ďǇ the additioŶ of 
luciferase substrates from the Dual Glo®Luciferase Assay System (Promega). The quantitation of the stable 
luminescent signals of both firefly and Renilla luciferase was detected with a Tecan-Infinite 200 Plate Reader. 
Data was processed by normalizing firefly luciferase signal with Renilla luciferase signal from each well. Each 
condition was repeated as technical triplicate and the whole experiment were performed as independent 
biological replicates. The percentages of β-catenin-dependent canonical Wnt pathway inhibition by StAx-
peptides were calculated with the GraphPad Prism 5 software (version 5.03). For calculation of IC50-values 
(Figure S2), non-linear regression analysis (four parameters, variable slope) was performed. 
Pull-Down Assay 
10 cm dishes from adherent DLD-1 cells (70-80% confluency) were lysed in 200 µL lysis buffer (20 mM HEPES 
pH 7.5, 10 mM KCl, 1 mM MgCl2, 1 mM Na2EDTA, 1 ŵM EGTA, aŶd ϭǆ Halt™ Protease IŶhiďitor CoĐktail 
(ThermoFisher Scientific) by four freeze-thaw cycles in liquid nitrogen, followed by sonication. Cell debris 
was removed by centrifugation for 20 min, 10,000 g, 4 °C, and protein concentration of the supernatant was 
measured using Bradford-Reagent (Serva). The lysate was diluted in binding buffer (50 mM TRIS pH 8.0, 
300 mM NaCl) to 1 mg/mL. Dynabeads® M-280 Streptavidin (ThermoFisher Scientific) with a loading capacity 
of 200 pŵol∙ŵg-1 were saturated with biotinylated b-StAx-h peptide for 1 h at room temperature on a 
rotating wheel. After washing three times in binding buffer, the beads were incubated with 1 mL cell lysate 
for 3 h at 4 °C on a rotating wheel. As a background control, Streptavidin beads alone were used. After 
washing the samples three times in binding buffer, samples were subjected to quantitative mass 
spectrometry.  
Mass Spectrometry of Pull-Down Assay 
Three replicates of peptide and control pull-downs were measured to obtain reliable label-free quantitative 
data. Before injection, samples were reduced, alkylated and digested directly on beads with LysC/Trypsin as 
previously described (Hubner et al. 2011). Obtained peptides were separated with a PepMap100 RSLC C18 
nano-HPLC column (2, 100, 75 IDx25 Đŵ, ŶaŶoViper, DioŶeǆ, GerŵaŶǇͿ oŶ aŶ UltiMate™ ϯϬϬϬ RSLCŶaŶo 
system (ThermoFisher Scientific) using a 125 min gradient from 5-60% acetonitrile with 0.1% formic acid and 
then directly sprayed via a nano-electrospray source (Nanospray Flex Ion Scource, Thermo Scientific) in a Q 
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Exactive
TM
 Plus Hybrid Quadrupole-Orbitrap Mass Spectrometer (ThermoFisher Scientific). The Q Exactive
TM
 
Plus was operated in a data-dependent mode acquiring one survey scan and subsequently ten MS/MS scans. 
Resulting raw files were processed with the MaxQuant software (version 1.5.2.18) searching against an 
uniprot human database (ref. Jan 2016) using deamidation (NQ), oxidation (M) and acetylation (N-terminus) 
as variable modifications and carbamidomethylation (C) as fixed modification (Cox et al. 2008). A false 
discovery rate cut off of 1% was applied at the peptide and protein level. The integrated label-free algorithm 
was used for relative quantification of the identified proteins (Cox et al. 2014). Quantified proteins were 
further analyzed with Perseus (version 1.5.5.5) (Tyanova et al. 2016). Potential candidates interacting with b-
StAx-h were required to be quantified in all three replicates (missing control values were imputated at the 
lower end of the distribution of all measured and quantified proteins) and were then identified with a two 
sample t-test. The result was visualized with a volcano plot (cut-off: p-value 0.01; S0 8). 
qRT-PCR from Small Intestinal Crypt Organoids 
Tet-O–β-catenin intestinal organoid culture was carried out as previously described (Sato et al. 2011): 
The small intestine was dissected and washed internally with cold PBS, then cut longitudinally. The villi were 
then scraped off prior to the intestine being cut into small pieces and washed copiously in PBS. The epithelial 
tissue layer fragments were released from the underlying mesenchyme and smooth muscle, following 
chelation in 2 mM EDTA/PBS under agitation at 4°C, by repeated washes and agitation in PBS to collect the 
fragments. The pooled fragments were centrifuged (500 g, 5 min), strained through 70 µm mesh (Greiner) 
and centrifuged again (250 g, 5 min). Crypt structures were seeded in Matrigel (Corning) at a density of 100-
ϮϬϬ∙ϱϬ µL-1 and grown in Advanced DMEM (Invitrogen) supplemented with 1x B27, 1x N2, 
Penicillin/Streptomycin, 0.2% Fungizone, 1x Glutamax, 10 mM final concentration HEPES (all Invitrogen), 
50 Ŷg∙ŵL-1 EGF (Sigma), 100 Ŷg∙ŵL-1 Noggin (Peprotech) and 400 Ŷg∙ŵL-1 R-spondin-1 (Peprotech). Structures 
start to bud after 2 days and were passaged every 7-10 days. Crypt structures were passaged by mechanical 
agitation in a 1 mL pipette tip, followed by centrifugation (250 g, 5 min) and seeding in fresh Matrigel (Jarde 
et al. 2013). Organoid cultures were routinely tested for mycoplasma (Lonza Myco Alert PLUS) and were 
found to be negative. Passage numbers 6-9 were used for drug assays. Crypt organoids were exposed to 
4 µg∙ŵL-1 doxycycline (dox) for 72 h; peptides were added to the medium for the last 2, 6, 10 or 24 h of the 
time course (final concentration 10 µM). The control treatment was exposure to dox for the whole time 
course of the experiment (in total 72 h). A dox withdrawal control was set up to make sure expression of 
Wnt responsive genes is dox-dependent. Organoids were exposed to 4 µg∙ŵL-1 dox for 48 h. Then organoids 
were then placed in dox-free medium and cultured for additional 24 h. Dox withdrawal over 24 h stops 
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eǆpressioŶ of ΔN-β-catenin and the consequent expression of Wnt responsive genes. The endpoint was qRT-
PCR of Wnt response biomarkers Axin2, Myc, Ascl2, Tiam1 and the Wnt pathway repressed differentiation 
marker Car4. Intestinal crypt structures were lysed in 800 µL Trizol (Invitrogen) per 50 µL Matrigel blob of 
crypt organoids for RNA purification followed by 0.2 mg (per 50 µL Matrigel blob) of the RNA co-precipitant 
glycogen (Ambion, 5 ŵg∙ŵL-1 stock). Chloroform/isoamyl alcohol mixture (Sigma) was added at 20 % Trizol 
volume to separate organic and aqueous layers and RNA was precipitated from the aqueous layer with 1 
volume isopropanol and centrifuged (12,000 g, 20 min) and the pellet washed 2x in 75% ethanol. DNA was 
reŵoǀed usiŶg the Turďo DNase kit ;AŵďioŶͿ usiŶg the ŵaŶufaĐturer’s iŶstruĐtioŶs. The reǀerse 
transcription reaction was carried out using the Improm II kit (Promega) on 700 ng RNA. Analysis with qRT-
PCR was carried out using the SensiFAST Sybr Hi-Rox 2x master mix (Bioline) using the manufacturer-
recommended cycling protocol. Details of primers used for qRT-PCR can be found in Fehler! Verweisquelle 
konnte nicht gefunden werden.. Relatiǀe eǆpressioŶ ǀalues ǁere ĐalĐulated usiŶg the ΔΔCT method.  
Viability Assay 
For CellTiter-Glo® Assay, ca. 5,000 cells were plated in 96-well plates (Corning) 24 h prior to assay start. Then, 
medium was carefully aspirated and cells were treated with fresh pre-warmed complete growth medium 
supplemented with varying peptide concentrations (0.5-10 µM peptide at a final concentration of 0.5 % 
DMSO) or DMSO vehicle control only for 72 h. AĐĐordiŶg to ŵaŶufaĐturer’s iŶstruĐtioŶs, plates aŶd reageŶts 
were equilibrated to room-temperature before one volume of CellTiter-Glo® reagent (Promega) was added 
to each well. For cell lysis, plates were shaken for 2 min on an orbital shaker. In order to obtain a stable 
signal, luminescence was recorded 10 min after reagent addition using a microplate reader (Safire2, Tecan).  
Wound-Closure Assay 
DLD-1 and MCF-7 cells were grown to confluence in 96-ǁell IŵageLoĐk™ plates ;EsseŶ BiosĐieŶĐesͿ iŶ 
complete groǁth ŵediuŵ. WouŶds ǁere geŶerated ǁith a WouŶdMaker™ deǀiĐe ĐreatiŶg a hoŵogeŶous 
700-800 µm scratch. Growth medium was then aspirated and cells were then washed twice with PBS, and 
treated with complete media supplemented with DMSO vehicle control or 10 µM peptides until the scratch 
wound was closed. Photographs were taken with IncuCyte® Zoom Live-Cell Analysis System (Essen 
Biosciences). The percentage of wound closure was calculated with IncuCyte® Zoom Software (Essen 
Biosciences) by measuring the width unoccupied by cells, and normalized to the zero time point.  
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QUANTIFICATION AND STATISTICAL ANALYSIS 
All data fitting and statistical analysis were performed using GraphPad Prism version 5.03 for Windows, 
GraphPad Software, La Jolla, California USA, www.graphpad.com. Statistical values including the exact n and 
statistical significance are also reported in the figure legends. For qRT-PCR on crypt organoids, viability and 
wound-closure assays, statistical significance was defined as p≤0.05 and determined by one-way ANOVA 
with Bonferroni's Multiple Comparison Test. Details on statistical analysis of the pull-down assay are 
explained in the corresponding STAR Methods section. 
